• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button Iconobesity

obesity

Page 3 of 12
Unemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobs
Success
Unemployed Brits will receive free Ozempic-style weight-loss shots to help them get jobs
By Orianna Rosa RoyleOctober 17, 2024
Companies are more willing to consider covering weight-loss drugs
Health
Companies are more willing to consider covering weight-loss drugs
By Chris MorrisOctober 10, 2024
Ozempic goes from threat to opportunity for packaged-food makers
Health
Ozempic goes from threat to opportunity for packaged-food makers
By Deena Shanker and BloombergOctober 2, 2024
As of March 2024, the Centers for Disease Control and Prevention no longer advises a five-day isolation period when you test positive for COVID-19, but recommends taking other precautions once your symptoms subside.
Health
Got COVID? Here are the new 2024 isolation guidelines
By Lindsey LeakeSeptember 27, 2024
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
Finance
Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
By Sara Sjolin, Sanne Wass, Oliver Crook and BloombergSeptember 23, 2024
Asian female doctor is working in laboratory wearing PPE. She holds an instrument and a petri dish.
Finance
Obesity drugmaker BioAge targets $158 million in IPO
By David Morris and BloombergSeptember 18, 2024
An Ozempic (semaglutide) injection pen is seen on a kitchen table.
Health
How Denmark got homegrown giant Novo Nordisk to lower Ozempic prices
By Arthur Allen and KFF Health NewsAugust 7, 2024
Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S's obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty Images
Retail
Europe’s most valuable company Novo Nordisk reports an uptick in profits as demand for weight-loss drugs continues to grow
By AFPAugust 7, 2024
Angela Fitch. cofounder and chief medical officer of knownwell.
Commentary
I’m an obesity medicine doctor and I’ve been on weight-loss drugs like Ozempic for a decade. Here’s why I think they aren’t a fad
By Angela FitchJuly 30, 2024
Thomas Schinecker, CEO of Roche Holding.
Retail
An obesity pill study tested on just 25 patients led to a stunning $16.8 billion increase in Swiss drugmaker Roche’s market value
By Naomi Kresge, Lisa Pham and BloombergJuly 23, 2024
Obesity medicine physician Dr. Nisha Patel breaks down five weight loss myths that “need to die” with Fortune.
Health
The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor
By Lindsey LeakeJuly 18, 2024
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
Health
Fake Ozempic and Wegovy are flooding the market. Here are 4 steps to avoid dangerous counterfeit weight loss drugs
By Amanda LoudinJune 27, 2024
EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
Health
EU urges clampdown on cosmetic misuse of Novo’s Ozempic amid worsening drug shortages for diabetics
By Naomi Kresge and BloombergJune 26, 2024
‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults
Health
‘My old doctor told me there was nothing he could do. He told me it was my fault’: Wegovy revolution sees 600% increase among young adults
By Jonel Aleccia and The Associated PressMay 22, 2024
Dr. Razia Hashmi, vice president of clinical affairs, Blue Cross Blue Shield Association, speaks during Fortune’s Brainstorm Health conference in Dana Point, Calif., on Tuesday, May 21, 2024.
Health
GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study
By Lindsey LeakeMay 22, 2024
1
  • 1
  • 2
  • 3
  • 4
  • 5
...12
Most Popular
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Success
Philanthropy leader at Warren Buffett and Bill Gates’ Giving Pledge says children of billionaires are pushing them to give their wealth away fasterplaceholder alt text
By Preston ForeJune 27, 2026
Success
Elon Musk on MacKenzie Scott giving away $26 billion of her fortune: 'Sadly,' it makes the world a worse placeplaceholder alt text
By Sydney LakeJune 29, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.